• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    36 Stocks Moving In Tuesday's Mid-Day Session

    3/29/22 12:03:04 PM ET
    $AVAH
    $BHIL
    $CELZ
    $CONN
    Medical/Nursing Services
    Health Care
    Packaged Foods
    Consumer Staples
    Get the next $AVAH alert in real time by email

    Gainers

    • China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) jumped 88.1% to $0.38 after declining 9% on Monday.
    • McCormick (NASDAQ:IGMS) shares jumped 49.8% to $22.46. Sanofi SA (NASDAQ:SNY) and IGM Biosciences signed an exclusive worldwide collaboration agreement for IgM antibodies agonists against three oncology targets and three immunology/inflammation targets.
    • The Lovesac Company (NASDAQ:LOVE) shares jumped 31% to $61.76. Lovesac reported fourth-quarter FY22 sales growth of 51.3% year-on-year, to $196.2 million, beating the consensus of $174.33 million.
    • Randolph Bancorp, Inc. (NASDAQ:RNDB) gained 25.6% to $26.50 after Hometown Financial Group announced plans to acquire Randolph Bancorp for $27 per share in cash.
    • Gelesis Holdings, Inc. (NYSE:GLS) gained 23.7% to $6.02. Gelesis Holdings recently reported FY EPS of $85.22.
    • Guardforce AI Co., Limited (NASDAQ:GFAI) rose 23.2% to $1.4550 after the company announced it is in the process of establishing subsidiaries in Dubai and Australia, with a focus on Robotics as a Service rollout initiatives.
    • Robinhood Markets, Inc. (NASDAQ:HOOD) gained 23.2% to $15.86. Robinhood Markets on Tuesday unveiled extended trading hours for its brokerage platform, building on the company's aim to make investing more accessible for all.
    • TRxADE HEALTH, Inc. (NASDAQ:MEDS) rose 22.4% to $2.8050 after the company reported Q4 earnings results.
    • Nielsen Holdings plc (NYSE:NLSN) jumped 20.8% to $26.83 after the company announced it will be acquire by a private equity consortium led by Evergreen Coast Capital and Brookfield Business Partners for $28 per share.
    • MicroVision, Inc. (NASDAQ:MVIS) gained 20.1% to $5.02. Microvision was granted US patent 'Alteration of resonant mode frequency response in mechanically resonant device.'
    • Grid Dynamics Holdings, Inc. (NASDAQ:GDYN) gained 15.6% to $13.67.
    • Molecular Templates, Inc. (NASDAQ:MTEM) jumped 14.8% to $3.10 as the company posted a narrower quarterly loss.
    • Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) gained 14.7% to $4.29 after the company reported better-than-expected Q4 sales results and issued FY22 sales guidance above analyst estimates.
    • Dave Inc. (NASDAQ:DAVE) jumped 14.3% to $7.45.
    • NexImmune, Inc. (NASDAQ:NEXI) rose 11.1% to $3.5990 after declining 24% on Monday.
    • Hycroft Mining Holding Corporation (NASDAQ:HYMC) shares rose 10.8% to $2.57 after jumping 80% on Monday.
    • Nautilus, Inc. (NYSE:NLS) gained 10.4% to $4.40.
    • ReShape Lifesciences Inc. (NASDAQ:RSLS) rose 9.6% to $1.48 after reporting a surge in FY21 sales.


    Losers

    • NeoGenomics, Inc. (NASDAQ:NEO) shares dipped 36.5% to $11.30 after the company announced it expects Q1 sales to be below its previously issued guidance range and withdrew its FY22 guidance. The company also announced Mark Mallon has agreed to step down as CEO.
    • Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) fell 26% to $3.99 after the company said FY21 EPS results were down from last year. The company also issued FY22 sales guidance below analyst estimates. B of A Securities downgraded the stock from Buy to Neutral and lowered the price target from $10 to $5.5.
    • Progenity, Inc. (NASDAQ:PROG) fell 25.2% to $1.2050 after reporting Q4 results.
    • Soleno Therapeutics, Inc. (NASDAQ:SLNO) fell 23.6% to $0.2197 after the company announced pricing of a roughly $15 million underwritten public offering.
    • Marin Software Incorporated (NASDAQ:MRIN) fell 18.4% to $2.9950 after jumping over 35% on Monday.
    • Stryve Foods, Inc. (NASDAQ:SNAX) shares fell 17.9% to $1.6376 after reporting weak quarterly sales.
    • SCYNEXIS, Inc. (NASDAQ:SCYX) dipped 17.7% to $3.87 following Q4 results.
    • Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) dropped 17.6% to $3.74.
    • Lipocine Inc. (NASDAQ:LPCN) shares fell 16.2% to $1.5250. Antares Pharma announced the FDA granted final approval for oral testosterone replacement therapy Tlando for conditions associated with a deficiency or absence of endogenous testosterone, or hypogonadism in adult males. Tlando was developed by Lipocine, with the company exclusively out-licensing the U.S. commercialization rights to Antares.
    • Ocuphire Pharma, Inc. (NASDAQ:OCUP) fell 14.8% to $3.6191 after the company reported topline results from MIRA-3 Phase 3 FDA registration trial for Nyxol® in the reversal of mydriasis.
    • Tellurian Inc. (NYSE:TELL) dropped 14.7% to $4.63.
    • Benson Hill, Inc. (NYSE:BHIL) fell 14.2% to $3.43. Barclays maintained Benson Hill (NYSE:BHIL) with an Overweight and lowered the price target from $10 to $8.
    • Kaixin Auto Holdings (NASDAQ:KXIN) fell 13% to $1.27. Kaixin shares jumped over 31% on Monday after the company announced an order for 20,000 electric vehicles.
    • Save Foods, Inc. (NASDAQ:SVFD) dropped 12.6% to $5.36.
    • Terran Orbital Corporation (NYSE:LLAP) fell 12.6% to $10.31.
    • Revelation Biosciences, Inc. (NASDAQ:REVB) dipped 12.2% to $2.07.
    • Sky Harbour Group Corporation (NYSE:SKYH) dropped 10.1% to $18.89.
    • Conn's, Inc. (NASDAQ:CONN) fell 7.1% to $18.97 following Q4 results.
    Get the next $AVAH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVAH
    $BHIL
    $CELZ
    $CONN

    CompanyDatePrice TargetRatingAnalyst
    Dave Inc.
    $DAVE
    2/9/2026Outperform
    Keefe Bruyette
    Robinhood Markets Inc.
    $HOOD
    2/9/2026$125.00Peer Perform → Outperform
    Wolfe Research
    Sanofi
    $SNY
    1/27/2026Neutral
    Citigroup
    Sanofi
    $SNY
    1/16/2026Buy → Neutral
    UBS
    Robinhood Markets Inc.
    $HOOD
    1/9/2026$145.00Buy
    Argus
    Sanofi
    $SNY
    1/6/2026Overweight → Equal Weight
    Barclays
    Robinhood Markets Inc.
    $HOOD
    12/29/2025$145.00 → $135.00Buy
    Needham
    Robinhood Markets Inc.
    $HOOD
    12/17/2025$155.00Buy
    Truist
    More analyst ratings

    $AVAH
    $BHIL
    $CELZ
    $CONN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Keefe Bruyette initiated coverage on Dave, Inc.

    Keefe Bruyette initiated coverage of Dave, Inc. with a rating of Outperform

    2/9/26 7:01:11 AM ET
    $DAVE
    Finance: Consumer Services
    Finance

    Robinhood Markets upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Robinhood Markets from Peer Perform to Outperform and set a new price target of $125.00

    2/9/26 6:55:42 AM ET
    $HOOD
    Investment Bankers/Brokers/Service
    Finance

    Citigroup initiated coverage on Sanofi

    Citigroup initiated coverage of Sanofi with a rating of Neutral

    1/27/26 8:49:24 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVAH
    $BHIL
    $CELZ
    $CONN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Sprott Eric bought $9,198,000 worth of shares (200,000 units at $45.99) (SEC Form 4)

    4 - HYCROFT MINING HOLDING CORP (0001718405) (Issuer)

    1/30/26 8:35:50 PM ET
    $HYMC
    Precious Metals
    Basic Materials

    Large owner Sprott Eric bought $4,996,000 worth of shares (100,000 units at $49.96) (SEC Form 4)

    4 - HYCROFT MINING HOLDING CORP (0001718405) (Issuer)

    1/27/26 9:16:28 PM ET
    $HYMC
    Precious Metals
    Basic Materials

    Large owner Sprott Eric exercised 4,672,352 shares at a strike of $6.00 and bought $6,642,000 worth of shares (200,000 units at $33.21) (SEC Form 4)

    4 - HYCROFT MINING HOLDING CORP (0001718405) (Issuer)

    1/15/26 8:04:28 PM ET
    $HYMC
    Precious Metals
    Basic Materials

    $AVAH
    $BHIL
    $CELZ
    $CONN
    SEC Filings

    View All

    SEC Form PRE 14A filed by Revelation Biosciences Inc.

    PRE 14A - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

    2/6/26 4:32:19 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Sanofi

    6-K - Sanofi (0001121404) (Filer)

    2/6/26 10:09:38 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hycroft Mining Holding Corporation filed SEC Form 8-K: Leadership Update, Shareholder Director Nominations, Other Events

    8-K - HYCROFT MINING HOLDING CORP (0001718405) (Filer)

    2/6/26 9:00:41 AM ET
    $HYMC
    Precious Metals
    Basic Materials

    $AVAH
    $BHIL
    $CELZ
    $CONN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 28, 2025 - FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors

    For Immediate Release: March 28, 2025 Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors (neutralizing antibodies).“Today’s approval of Qfitlia is significant for patients wi

    3/28/25 10:17:55 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    February 14, 2025 - FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes

    For Immediate Release: February 14, 2025 Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA. As a rapid-acting insulin, Meri

    2/14/25 3:00:13 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SOLIQUA 100/33 issued to SANOFI-AVENTIS US

    Submission status for SANOFI-AVENTIS US's drug SOLIQUA 100/33 (SUPPL-14) with active ingredient INSULIN GLARGINE; LIXISENATIDE has changed to 'Approval' on 11/01/2024. Application Category: BLA, Application Number: 208673, Application Classification:

    11/4/24 4:49:34 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVAH
    $BHIL
    $CELZ
    $CONN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Guardforce AI Signs Non-binding Letter of Intent to Acquire Leading AI-Powered Speech Therapy and Development Platform

    NEW YORK, NY, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Guardforce AI Co., Limited ("Guardforce AI" or the "Company") (NASDAQ:GFAI, GFAIW)), an AI-driven technology company providing Agentic AI, smart solutions in automation, robotics, and secured logistics, today announced it has entered into a non-binding Letter of Intent (LOI) to acquire 100% of the issued and outstanding share capital of MGAI Limited ("MGAI"), a pioneer in AI-driven solutions for speech therapy and development management and rehabilitation services. Utilizing advanced AI technology and one of China's largest domestic databases for children's language development assessment, MGAI has built a service ecosystem combining proprie

    2/9/26 8:30:00 AM ET
    $GFAI
    Diversified Commercial Services
    Consumer Discretionary

    Dave Reports Preliminary Fourth Quarter and Full Year 2025 Results

    2025 Revenue and Adjusted EBITDA Results are Expected to Exceed the Top-End of Guidance 4Q25 28 DPD Rate Expected to be Within the Range of 1.95%-2.00%, Outperforming Guidance of Below 2.10% Full Earnings Results and 2026 Financial Outlook to Be Discussed on March 2, 2026 at 5:00pm ET LOS ANGELES, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Dave Inc. ("Dave" or the "Company") (NASDAQ:DAVE), one of the nation's leading neobanks, today announced certain preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025. The Company expects to release full, audited financial results and file its annual report on Form 10-K for the year ended December 31, 2025 on Mar

    2/5/26 4:15:00 PM ET
    $DAVE
    Finance: Consumer Services
    Finance

    Ginkgo Bioworks' Autonomous Laboratory Driven by OpenAI's GPT-5 Achieves 40% Improvement Over State-of-the-Art Scientific Benchmark

    Research conducted in collaboration with OpenAI using Ginkgo's cloud laboratoryPreprint describes how GPT-5-driven autonomous lab significantly reduced reaction costs in cell-free protein synthesisGPT-5-driven autonomous lab executed over 36,000 experimentsGinkgo now selling the AI-improved reaction mix in its reagents store, showing commercial potential of AI-driven scienceBOSTON, Feb. 5, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA) today announced it has demonstrated, in collaboration with OpenAI, an AI system that autonomously designed, executed, and learned from biological experiments with minimal human involvement. In a new preprint, the company reports the system reduced cell-free p

    2/5/26 2:00:00 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVAH
    $BHIL
    $CELZ
    $CONN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Interim CFO Hrynewich Stephen converted options into 4,800 shares and covered exercise/tax liability with 1,477 shares, increasing direct ownership by 2% to 159,456 units (SEC Form 4)

    4 - MICROVISION, INC. (0000065770) (Issuer)

    2/9/26 4:50:32 PM ET
    $MVIS
    Industrial Machinery/Components
    Technology

    Director Heyer Andrew R was granted 279 shares, increasing direct ownership by 0.11% to 250,643 units (SEC Form 4)

    4 - Lovesac Co (0001701758) (Issuer)

    2/5/26 5:55:11 PM ET
    $LOVE
    Other Specialty Stores
    Consumer Discretionary

    Director Roper Jess covered exercise/tax liability with 1,591 shares, decreasing direct ownership by 11% to 12,828 units (SEC Form 4)

    4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

    2/5/26 5:31:20 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVAH
    $BHIL
    $CELZ
    $CONN
    Leadership Updates

    Live Leadership Updates

    View All

    Dave Inc. Appoints Nima Khajehnouri to Board of Directors; Announces Board Leadership Transitions

    LOS ANGELES, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Dave Inc. ("Dave" or the "Company") (NASDAQ:DAVE), one of the nation's leading neobanks, today announced that Nima Khajehnouri, a distinguished leader in artificial intelligence and data engineering, has joined its Board of Directors, effective immediately. Mr. Khajehnouri will serve as a member of the Company's Audit Committee. Imran Khan, who has served on the Board since August 2023, is stepping down in conjunction with this appointment. Mr. Khajehnouri brings more than two decades' experience of leading engineering at some of the world's most influential technology companies. He currently serves as Vice President of Engineering at Meta, h

    1/20/26 5:27:46 PM ET
    $DAVE
    Finance: Consumer Services
    Finance

    NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue

    – Anticipates preliminary unaudited fourth quarter 2025 revenue of approximately $190 million; full-year 2025 revenue of $727 million – – Announces Chief Financial Officer transition – NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced preliminary fourth quarter and full-year 2025 revenue and also announced a transition of the Company's Chief Financial Officer. Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue For the fourth quarter of 2025, NeoGenomics expects to report total revenue of approximately $190 million, representing year-over-year growth of 11%. For the full-year 2025, Neo

    1/12/26 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. "Jack" Kenny to its Board of Directors

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of diagnostics and lab services industry veteran John P. "Jack" Kenny to its Board of Directors. Mr. Kenny is filling the seat vacated by Alison Hannah, MD, who is rotating off the Board after more than ten years of dedicated service. Mr. Kenny brings to the NeoGenomics Board over three decades of diverse executive, commercial, and operational experience and a track record of success in the diagnostics and lab services businesses. He most recently served as President, Chief Executive Officer and Board Director of Meridian Bioscience, a fully i

    12/30/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    $AVAH
    $BHIL
    $CELZ
    $CONN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Soleno Therapeutics Inc.

    SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    11/19/24 9:44:27 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Molecular Templates Inc.

    SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)

    11/18/24 9:49:56 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

    SC 13G/A - SCYNEXIS INC (0001178253) (Subject)

    11/14/24 7:07:26 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVAH
    $BHIL
    $CELZ
    $CONN
    Financials

    Live finance-specific insights

    View All

    Dave Reports Preliminary Fourth Quarter and Full Year 2025 Results

    2025 Revenue and Adjusted EBITDA Results are Expected to Exceed the Top-End of Guidance 4Q25 28 DPD Rate Expected to be Within the Range of 1.95%-2.00%, Outperforming Guidance of Below 2.10% Full Earnings Results and 2026 Financial Outlook to Be Discussed on March 2, 2026 at 5:00pm ET LOS ANGELES, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Dave Inc. ("Dave" or the "Company") (NASDAQ:DAVE), one of the nation's leading neobanks, today announced certain preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025. The Company expects to release full, audited financial results and file its annual report on Form 10-K for the year ended December 31, 2025 on Mar

    2/5/26 4:15:00 PM ET
    $DAVE
    Finance: Consumer Services
    Finance

    Grid Dynamics to Announce Fourth Quarter and Full Year 2025 Financial Results on March 5th

    Grid Dynamics Holdings, Inc. (NASDAQ:GDYN) ("Grid Dynamics"), a leader in enterprise-level digital transformation services and solutions, today announced that it will host a video conference call at 4:30 p.m. ET on Thursday, March 5, 2026 to discuss its fourth quarter and full year 2025 financial results. A press release containing these results will be available on our website prior to the call. A webcast of the video conference call, as well as a replay available after the event, can be accessed on the Investor Relations section of the company's website at https://www.griddynamics.com/investors. About Grid Dynamics Grid Dynamics (NASDAQ:GDYN) is a leading provider of technology cons

    2/5/26 9:15:00 AM ET
    $GDYN
    Computer Software: Prepackaged Software
    Technology

    NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its fourth quarter and full year 2025 financial results prior to the open of the U.S. financial markets on Tuesday, February 17, 2026. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 5

    1/27/26 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care